Dr Aaron Wetten
Dr Jess Dyson
Professor David Jones
| Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? | 2024 |
|
Dr Aaron Wetten
Dr Jess Dyson
Professor David Jones
| Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis | 2024 |
|
Dr Aaron Wetten
Dr Jess Dyson
Professor David Jones
| Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis | 2022 |
|
Dr Aaron Wetten
Dr Laura Ogle
Dr George Mells
Dr Vinod Hegade
Dr Laura Jopson
et al. | Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis? | 2022 |
|
Professor David Jones
Dr Aaron Wetten
Dr Ben Barron-Millar
Dr Laura Ogle
Dr George Mells
et al. | The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study | 2022 |
|
Dr Rebecca Dunn
Dr Aaron Wetten
Professor Stuart McPherson
| Viral hepatitis in 2021: The challenges remaining and how we should tackle them | 2022 |
|
Dr Kate Hallsworth
Shion Gosrani
Sarah Hogg
Dr Aaron Wetten
Professor Stuart McPherson
et al. | Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C | 2021 |
|
Dr Aaron Wetten
Professor David Jones
Dr Jess Dyson
| Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough? | 2021 |
|
Professor Stuart McPherson
Shion Gosrani
Sarah Hogg
Dr Aaron Wetten
Dr Kate Hallsworth
et al. | Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C | 2020 |
|
